December 15, 2017 / 12:30 PM / 6 months ago

BRIEF-Takeda And Tigenix Announces That CX601 Has Received a Positive CHMP Opinion

Dec 15 (Reuters) - TIGENIX NV:

* REG-TAKEDA AND TIGENIX ANNOUNCE THAT CX601 (DARVADSTROCEL) HAS RECEIVED A POSITIVE CHMP OPINION TO TREAT COMPLEX PERIANAL FISTULAS IN CROHN’S DISEASE

* ‍FIRST ALLOGENEIC STEM CELL THERAPY TO RECEIVE POSITIVE CHMP OPINION IN EUROPE​

* ‍CX601 OFFERS POTENTIAL NEW TREATMENT OPTION FOR PATIENTS WHO DO NOT RESPOND TO CURRENT AVAILABLE THERAPIES AND ARE SUBJECT TO NUMEROUS INVASIVE SURGERIES​

* ‍RECEIPT OF MA WILL TRIGGER A MILESTONE PAYMENT FROM TAKEDA TO TIGENIX OF EUR 15 MILLION​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below